EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma

Meaghan Polack iD, Gabi W van Pelt iD, Davita H van den Heuvel, Elma Meershoek Klein-Kranenbarg iD, Annet G H Roodvoets iD, Hein Putter iD, Augustinus S L P Crobach iD, Iris D Nagtegaal iD, Koen C M J Peeters iD, Rob A E M Tollenaar iD, J Han J M van Krieken iD, Wilma E Mesker iD

Histopathology · 2025-07 · 87 (1) · 44-57

DOI: 10.1111/his.15423 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Histopathology, online erschienen am 04.04.2025. Verfasst von Meaghan Polack und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Rectal Neoplasms, Stromal Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bollenstreekfonds, Hillegom, the Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tumour–stroma ratio (TSR) scores of biopsy material in rectal carcinoma (RC) could aid a biomarker‐based, upfront and personalised treatment strategy selection for RC patients. In a large retrospective, multicentre cohort, we aimed to validate the predictive value of biopsy‐scored TSR on neoadjuvant therapy response, and secondarily, disease‐free and overall survival (DFS, OS). Methods and results Scanned haematoxylin and eosin‐stained RC biopsy slides were collected from Leiden University Medical Center ( N = 116) and from the clinical PROCTOR‐SCRIPT ( N = 142) and RAPIDO ( N = 271) trials. TSR was scored per protocol and categorised as stroma‐low (≤ 50%) or stroma‐high (> 50%). Major response was defined as tumour regression grade (TRG) 1 + 2 by Mandard, including pathological complete response. Ultimately, a large and varied cohort with 373 RC patients was established. Locally advanced RC was more often stroma‐high ( P < 0.001). We subsequently observed significantly lower major response rates in the stroma‐high RC after a neoadjuvant treatment approach (hazard ratio = 0.63, 95% confidence interval = 0.41–0.99; P = 0.044). Despite correction for well‐known risk factors in Cox hazard regression analysis, such as (y)pTNM substages or residual tumour status, the TSR had no singular significant influence on DFS nor OS in multivariate analysis ( P = 0.438; P = 0.934, respectively).

Conclusions

Biopsy‐scored TSR can predict neoadjuvant therapy efficacy, as RC patients with stroma‐high biopsies show less major response. However, patient survival is multifactorial, although response is an important predictor, influenced by TSR. Scoring TSR on RC biopsy material is a reliable histological parameter, implementation of which in treatment guidelines could improve upfront selection for a watch‐and‐wait strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsStromal CellsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedNeoadjuvant TherapyBiopsyAdultDisease-Free SurvivalAged, 80 and overPrognosis

Stichwörter der Autor:innen

neoadjuvant treatmentpredictionrectal cancertumour microenvironmenttumour regression gradetumour responsetumour–stroma ratio

Autor:innen und Institutionen

  • Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
  • Clinical Research Center, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

ORCID-Profile: Meaghan Polack, Gabi W van Pelt, Elma Meershoek Klein-Kranenbarg, Annet G H Roodvoets, Hein Putter, Augustinus S L P Crobach, Iris D Nagtegaal, Koen C M J Peeters, Rob A E M Tollenaar, J Han J M van Krieken, Wilma E Mesker

Förderung

  • Bollenstreekfonds, Hillegom, the Netherlands

Zitieren

APA

Polack, M., van Pelt, G. W., van den Heuvel, D. H., Klein-Kranenbarg, E. M., Roodvoets, A. G. H., Putter, H., Crobach, A. S. L. P., Nagtegaal, I. D., Peeters, K. C. M. J., Tollenaar, R. A. E. M., van Krieken, J. H. J. M., & Mesker, W. E. (2025). The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma. Histopathology, 87(1), 44-57. https://doi.org/10.1111/his.15423

Vancouver

Polack M, van Pelt GW, van den Heuvel DH, Klein-Kranenbarg EM, Roodvoets AGH, Putter H, et al. The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma. Histopathology. 2025;87(1):44-57. doi:10.1111/his.15423

BibTeX
@article{Polack2025,
  author = {Polack, Meaghan and van Pelt, Gabi W and van den Heuvel, Davita H and Klein-Kranenbarg, Elma Meershoek and Roodvoets, Annet G H and Putter, Hein and Crobach, Augustinus S L P and Nagtegaal, Iris D and Peeters, Koen C M J and Tollenaar, Rob A E M and van Krieken, J Han J M and Mesker, Wilma E},
  title = {The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma},
  journal = {Histopathology},
  year = {2025},
  volume = {87},
  number = {1},
  pages = {44--57},
  doi = {10.1111/his.15423}
}
Kostenlos starten →